Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Abiogen Pharma S P A manages a company patent portfolio situated in the Biotechnology & Pharmaceuticals technology area. The portfolio currently has 1 pending office action. This workload is assigned to 1 distinct examiner working within 1 distinct art unit, which demonstrates a highly centralized prosecution environment for the company's active filings. This level of concentration is often seen in portfolios where the intellectual property strategy is targeted toward a specific pharmaceutical innovation.
The busiest examiner for this portfolio is MCMILLIAN, KARA RENITA, who is responsible for 1 busiest examiner pending office action. Since the total pending office actions for the company is 1, this examiner is handling all current responses required by the office. The presence of only 1 distinct art unit indicates that the company's current patenting activity is confined to a specific technical niche within the broader biotechnology sector. Consequently, the company's current prosecution progress is entirely subject to the review and feedback of this 1 examiner.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MCMILLIAN, KARA RENITA | 1 | 30.9% | +37.9% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17632841 | CHOLECALCIFEROL FOR USE IN THE TREATMENT OF CELIAC DISEASE | MCMILLIAN, KARA RENITA | 46d overdue |
| Art Unit | Apps |
|---|---|
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17632841 | CHOLECALCIFEROL FOR USE IN THE TREATMENT OF CELIAC DISEASE | MCMILLIAN, KARA RENITA | 1623 | §103 | Non-Final OA | 46d overdue | Pending | Feb 04, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAbiogen Pharma S P A has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Kara Renita Mcmillian has the most, with 1 of Abiogen Pharma S P A's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
